AEON Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on January 21, 2026. AEON Biopharma, Inc. (AEON), an emerging growth company incorporated in Delaware, reported the consummation of a debt-for-equity exchange with Daewoong Pharmaceutical Co., LTD. ("Daewoong") and the results of a Special Meeting of Stockholders held on the same date.
Key Financial Metrics and Capital Structure
The filing details a significant restructuring of debt and equity rather than operational financial performance metrics (revenue, profit, or cash flow are not reported in this document).
- Debt Restructuring: Satisfied obligations under senior secured convertible notes ("Old Notes") with a principal amount of up to $15,000,000.
- New Debt Issuance: Issued a new senior secured convertible note ("New Note") with a principal amount of $1,500,000 to Daewoong.
- Equity Issuance (Exchange): Issued 11,918,380 shares of Class A Common Stock and 11,236,631 pre-funded warrants to Daewoong.
- Warrant Issuance (Exchange): Issued warrants to purchase up to 8,000,000 shares of Common Stock at an exercise price of $1.09392 per share.
- Outstanding Shares: Immediately following the exchange, 24,024,282 shares of Common Stock were outstanding.
Material Changes and Corporate Actions
The primary material change is the conversion of a significant portion of Daewoong's debt holdings into equity and new debt instruments. Additionally, the company secured stockholder approval for a Private Investment in Public Equity (PIPE) financing and an updated equity incentive plan.
- Debt-to-Equity Swap: The exchange reduced the company's immediate debt burden by converting $15 million in old notes into equity and a smaller $1.5 million new note.
- License Agreement Amendment: Entered into a Fifth Amendment to the License and Supply Agreement with Daewoong. The "Termination Purchase Right" will expire upon Daewoong's sale of 50% of its Common Stock holdings.
- Stockholder Approvals: Stockholders approved four proposals at the Special Meeting, including the PIPE Financing, the Exchange Proposal, and the Amended and Restated 2023 Incentive Award Plan.
Guidance, Outlook, and Future Events
Management indicated the expected timing for the second closing of a Private Placement transaction.
- Private Placement Second Closing: Expected to occur the week of January 26, 2026.
- Expected Issuance at Second Closing: Subject to conditions, the company expects to issue and sell 4,616,924 shares (or pre-funded warrants), 6,581,829 warrants, and up to 6,581,829 True-Up Warrants to investors.
- Equity Plan: The 2023 Incentive Award Plan was approved to increase the number of shares authorized for issuance under the plan.
Investor Verification Checklist
- Verify the final closing date and total capital raised from the Private Placement Second Closing expected the week of January 26, 2026.
- Confirm the dilution impact of the 11.9 million shares and 11.2 million pre-funded warrants issued to Daewoong on existing shareholders.
- Review the full text of the Fifth Amendment to the License and Supply Agreement (Exhibit 10.2) to understand the specific terms of the terminated Termination Purchase Right.
- Monitor the company's cash runway given the conversion of debt to equity and the timing of the remaining private placement funds.
- Check subsequent filings for the final number of shares issued under the 2023 Incentive Award Plan.